Discovery Formulations: Approaches and Practices in Early Preclinical Development-Reference-Cited by-同舟云学术

Discovery Formulations: Approaches and Practices in Early Preclinical Development

Published:2014-09-27 Issue: Volume: Page:49-94
ISSN:2210-7371
Container-title:Discovering and Developing Molecules with Optimal Drug-Like Properties
language:
Short-container-title:

Author:

Bhattachar Shobha N.,Bender David M.,Sweetana Stephanie A.,Wesley James A.

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-1-4939-1399-2_2

Reference124 articles.

1. Akimoto M, Nagahata N et al (2000) Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm 49(2):99–102

2. Anderson GD, Saneto RP (2012) Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev 64(10):911–918

3. Balazs O (2011) Preclinical formulation in early drug research. In: Tihanyi K, Vastag M (eds) Solubility, delivery and ADME problems of drugs and drug candidates. Budapest, Bentham, p 22

4. Bernabei R, Rossini PM et al (2012) Compliance and caregiver satisfaction in Alzheimer’s disease: results from the AXEPT study. Dement Geriatr Cogn Dis Extra 2(1):418–432

5. Bhattachar SN, Perkins EJ et al (2011) Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus, simulations to predict absorption. J Pharm Sci 100(11):4756–4765

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustained release ocular drug delivery systems for glaucoma therapy;Expert Opinion on Drug Delivery;2023-06-12

2. Pre-clinical Formulation Development of an in situ Meglumine Salt of AZD5991: A Novel Macrocyclic Mcl-1 Inhibitor;Pharmaceutical Research;2023-04

3. The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules;The AAPS Journal;2020-01-03

4. Preclinical Formulation Assessment ofNCEs;Innovative Dosage Forms;2019-10-07

5. Preclinical Safety Aspects for Excipients: Oral,IV,and Topical Routes;Innovative Dosage Forms;2019-10-07